Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
Gießen
DVG Service GmbH
2020
|
| Ausgabe: | 1. Auflage |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | IX, 128 Seiten Illustrationen, Diagramme 21 cm |
| ISBN: | 9783863455347 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV046896117 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 200911s2020 gw a||| m||| 00||| eng d | ||
| 015 | |a 20,B35 |2 dnb | ||
| 015 | |a 20,H09 |2 dnb | ||
| 016 | 7 | |a 1215046308 |2 DE-101 | |
| 020 | |a 9783863455347 |c Broschur |9 978-3-86345-534-7 | ||
| 035 | |a (OCoLC)1159698420 | ||
| 035 | |a (DE-599)HEB465982492 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-188 | ||
| 084 | |a 630 |2 sdnb | ||
| 084 | |a 616.994 |2 sdnb | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Schadel, Dina |e Verfasser |0 (DE-588)1212543882 |4 aut | |
| 245 | 1 | 0 | |a Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors |c eingereicht von Dina Schadel, geb. Kleinlützum |
| 250 | |a 1. Auflage | ||
| 264 | 1 | |a Gießen |b DVG Service GmbH |c 2020 | |
| 300 | |a IX, 128 Seiten |b Illustrationen, Diagramme |c 21 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |b Dissertation |c Justus-Liebig-Universität Gießen |d 2019 | ||
| 650 | 7 | |a cell lines |2 cabt | |
| 650 | 7 | |a viruses |2 cabt | |
| 650 | 7 | |a antibodies |2 cabt | |
| 650 | 7 | |a neoplasms |2 cabt | |
| 650 | 7 | |a growth models |2 cabt | |
| 653 | |a Onkolytische Viren | ||
| 653 | |a Glioblastoma Multiforme | ||
| 653 | |a HepatozellulÃres Karzinom | ||
| 653 | |a Krebsstammzellen | ||
| 653 | |a CD133 | ||
| 653 | |a Oncolytic Viruses | ||
| 653 | |a Glioblastoma Multiforme | ||
| 653 | |a Hepatocellular Carcinoma | ||
| 653 | |a Cancer Stem Cells | ||
| 653 | |a CD133 | ||
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u https://d-nb.info/1215046308/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032305876&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-032305876 | ||
Datensatz im Suchindex
| _version_ | 1804181764234543104 |
|---|---|
| adam_text | T
ABLE
OF
C
ONTENTS
1.
I
NTRODUCTION
.......................................................................................
5
1.1.
CANCER
STEM
CELLS
..........................................................................................
5
1.2.
CD133
AS
MARKER
FOR
CANCER
STEM
CELLS
.....................................................
7
1.3.
MALIGNANT
GLIOMA
............................................................................................
8
1.3.1.
RELEVANCE
OF
CD133
IN
GLIOBLASTOMA
MULTIFORME
........................................
10
1.4.
HEPATOCELLULAR
CARCINOMA
............................................................................
11
1.4.1.
RELEVANCE
OF
CD1
33
IN
HEPATOCELLULAR
CARCINOMA
......................................
13
1.5.
VIRUSES
USED
AS
ONCOLYTIC
AGENTS
.............................................................
13
1.5.1.
MEASLES
VIRUS
................................................................................................
14
1.5.2.
VESICULAR
STOMATITIS
VIRUS
.............................................................................
21
1.6.
TARGETED
ONCOLYTIC
MEASLES
VIROTHERAPY
..................................................25
1.6.1.
CD133-TARGETED
ONCOLYTIC
MEASLES
VIRUS
...................................................
26
1.7.
OBJECTIVE
.........................................................................................................
28
2.
M
ATERIAL
AND
M
ETHODS
......................................................................
30
2.1.
MATERIALS
.........................................................................................................
30
2.1.1.
CONSUMABLES
.................................................................................................
30
2.1.2.
CHEMICALS
AND
REAGENTS
.............................................................................
31
2.1.3. BUFFERS
AND
MEDIA
.........................................................................................
33
2.1.4.
COMMERCIALLY
AVAILABLE
KITS
.........................................................................
33
2.1.5.
ANTIBODIES
......................................................................................................
34
2.1.6.
CELL
LINES
.......................................................................................................
35
2.1.7.
VIRUSES
...........................................................................................................
36
2.1.8. MEDICALS
AND
ANESTHETICS
.............................................................................
36
2.1.9.
INSTRUMENTS
....................................................................................................
37
2.1.10.
SOFTWARE
.........................................................................................................
38
2.2.
PROTEIN
BIOMEDICAL
METHODS
.......................................................................
39
2.2.1. SODIUM
DODECYL
SULFATE-POLYACRYLAMIDE
GEL
ELECTROPHORESIS
...................
39
2.2.2.
IMMUNOBLOT
...................................................................................................
40
2.3.
CELL
CULTURE
AND
VIROLOGICAL
METHODS
.......................................................40
2.3.1.
CULTIVATION
OF
CELL
LINES
................................................................................
41
2.3.2.
FREEZING
AND
THAWING
OF
CELLS
.....................................................................
41
2.3.3.
ISOLATION
AND
CULTIVATION
OF
HUMAN
CD34
+
CELLS
...........................................
42
2.3.4.
FLOW
CYTOMETRY
ANALYSIS
...............................................................................
42
2.3.5.
PREPARATION
OF
VIRUS
STOCKS
...........................................................................
44
2.3.6.
TITRATION
OF
VIRUS
PARTICLES
(TCID50)
..............................................................
45
2.3.7.
INFECTION
OF
CELLS
............................................................................................
45
2.3.8.
COLONY-FORMING
ASSAYS
................................................................................
47
2.3.9.
VIRUS
GROWTH
KINETICS
....................................................................................
47
2.3.10.
KILLING
KINETICS
AND
DOSE
DEPENDENCY
.........................................................
48
2.3.11.
BYSTANDER
ASSAY
............................................................................................
49
2.4.
ANIMAL
EXPERIMENTS
......................................................................................49
2.4.1.
SUBCUTANEOUS
HUH7
XENOGRAFT
CELL
IMPLANTATION
......................................
50
2.4.2.
ORTHOTOPIC
GLIOMA
SPHERE
CELL
IMPLANTATION
................................................
51
2.4.3.
ADMINISTRATION
OF
VIRUS
PARTICLES
...................................................................
52
2.4.4.
TRANSCARDIAL
PERFUSION
..................................................................................
53
2.4.5.
EX
VIVO
SPHERE
FORMATION
ASSAYS
...............................................................
53
2.4.6.
CRYO
EMBEDDING
AND
IMMUNOFLUORESCENCE
STAINING
OF
TUMOR
SECTIONS
...54
2.4.7. PARAFFIN
EMBEDDING
AND
IMMUNOHISTOCHEMISTRY
OF
BRAIN
SECTIONS
............
54
2.4.8.
QUANTIFICATION
OF
INFECTED
AREAS
IN
CRYO
SECTIONS
OF
TUMOR
TISSUE
...........
55
2.5.
STATISTICAL
ANALYSIS
.........................................................................................
56
3.
R
ESULTS
................................................................................................
57
3.1.
CHARACTERIZATION
OF
ONCOLYTIC
VIRUSES
FOR
PROTEIN
COMPOSITION
.........
58
3.2.
SELECTIVITY
OF
TARGETED
ONCOLYTIC
VIRUSES
.................................................
58
3.3.
REPLICATION
OF
TARGETED
ONCOLYTIC
VIRUSES
ON
HUH7
HEPATOCELLULAR
CARCINOMA
CELLS
.................................................................
60
3.4.
TOXICITY
TESTING
OF
CD133-TARGETED
ONCOLYTIC
VIRUSES
TOWARDS
HUMAN
CD34
+
CELLS
........................................................................
62
3.4.1.
ANALYSIS
OF
HUMAN
CD34
+
CELLS
FOR
SUSCEPTIBILITY
TO
INFECTION
...................
63
3.4.2.
EVALUATION
OF
IMPAIRMENT
OF
HEMATOPOIETIC
STEM
CELL
SELF-RENEWAL
AFTER
INFECTION
.........................................................................
65
3.5.
ONCOLYTIC
PROPERTIES
ON
CULTURED
CELLS
.....................................................
67
3.5.1.
INFECTION
OF
HEPATOCELLULAR
CARCINOMA
CELLS
................................................
67
3.5.2.
POTENTIATED
ONCOLYSIS
OF
MV
SCD
-CD133
THROUGH
BYSTANDER-MEDIATED
KILLING
OF
TARGET-RECEPTOR
NEGATIVE
CELLS
....................................................
70
3.6.
ONCOLYTIC
PROPERTIES
ON
PRIMARY
TUMOR
CELLS
.........................................
71
3.6.1.
CELL
SURFACE
EXPRESSION
LEVELS
OF
CD46
AND
CD133
ON
NCH644
CELLS....
73
3.6.2.
TIME
AND
DOSE
RESPONSE
KILLING
OF
PRIMARY
GLIOMA
SPHERE
CELLS
...........
74
3.6.3.
ENHANCED
KILLING
OF
PRIMARY
GLIOMA
SPHERE
CELLS
BY
MV
SCD
-CD133
........
76
3.7.
EFFICACY
IN
VIVO
.............................................................................................
77
3.7.1.
ACTIVITY
OF
INTRATUMORALLY
APPLIED
CD133-TARGETED
VIRUSES
IN
A
SUBCUTANEOUS
XENOGRAFT
MODEL
OF
HEPATOCELLULAR
CARCINOMA
...................
77
3.7.2.
CHARACTERIZATION
OF
EXPLANTED
TUMORS
INFECTED
WITH
MV-CD133
AND
VSV-CD133
........................................................................
79
3.7.3.
ACTIVITY
OF
SYSTEMICALLY
ADMINISTERED
CD133-TARGETED
VIRUSES
AGAINST
A
SUBCUTANEOUS
XENOGRAFT
MODEL
OF
HEPATOCELLULAR
CARCINOMA
................
85
3.7.4.
ACTIVITY
OF
CD133-TARGETED
VIRUSES
IN
AN
ORTHOTOPIC
GLIOMA
MODEL
...........
85
3.7.5.
DIRECT
INTRACRANIAL
APPLICATION
OF
ONCOLYTIC
VIRUSES
INTO
NAIVE
MICE
...........
91
4.
D
ISCUSSION
...........................................................................................
93
4.1.
CD133
AS
TARGET
RECEPTOR
...........................................................................
93
4.2.
NEUROTOXICITY
..................................................................................................
98
4.3.
CLINICAL
APPLICATION
OF
RECEPTOR-TARGETED
ONCOLYTIC
VIRUSES
............
102
R
EFERENCES
.............................................................................................
105
L
IST
O
F
P
UBLICATIONS
..............................................................................
124
D
ANKSAGUNG
............................................................................................
127
E
HRENWORTLICHE
E
RKLARUNG
.................................................................
128
|
| adam_txt |
T
ABLE
OF
C
ONTENTS
1.
I
NTRODUCTION
.
5
1.1.
CANCER
STEM
CELLS
.
5
1.2.
CD133
AS
MARKER
FOR
CANCER
STEM
CELLS
.
7
1.3.
MALIGNANT
GLIOMA
.
8
1.3.1.
RELEVANCE
OF
CD133
IN
GLIOBLASTOMA
MULTIFORME
.
10
1.4.
HEPATOCELLULAR
CARCINOMA
.
11
1.4.1.
RELEVANCE
OF
CD1
33
IN
HEPATOCELLULAR
CARCINOMA
.
13
1.5.
VIRUSES
USED
AS
ONCOLYTIC
AGENTS
.
13
1.5.1.
MEASLES
VIRUS
.
14
1.5.2.
VESICULAR
STOMATITIS
VIRUS
.
21
1.6.
TARGETED
ONCOLYTIC
MEASLES
VIROTHERAPY
.25
1.6.1.
CD133-TARGETED
ONCOLYTIC
MEASLES
VIRUS
.
26
1.7.
OBJECTIVE
.
28
2.
M
ATERIAL
AND
M
ETHODS
.
30
2.1.
MATERIALS
.
30
2.1.1.
CONSUMABLES
.
30
2.1.2.
CHEMICALS
AND
REAGENTS
.
31
2.1.3. BUFFERS
AND
MEDIA
.
33
2.1.4.
COMMERCIALLY
AVAILABLE
KITS
.
33
2.1.5.
ANTIBODIES
.
34
2.1.6.
CELL
LINES
.
35
2.1.7.
VIRUSES
.
36
2.1.8. MEDICALS
AND
ANESTHETICS
.
36
2.1.9.
INSTRUMENTS
.
37
2.1.10.
SOFTWARE
.
38
2.2.
PROTEIN
BIOMEDICAL
METHODS
.
39
2.2.1. SODIUM
DODECYL
SULFATE-POLYACRYLAMIDE
GEL
ELECTROPHORESIS
.
39
2.2.2.
IMMUNOBLOT
.
40
2.3.
CELL
CULTURE
AND
VIROLOGICAL
METHODS
.40
2.3.1.
CULTIVATION
OF
CELL
LINES
.
41
2.3.2.
FREEZING
AND
THAWING
OF
CELLS
.
41
2.3.3.
ISOLATION
AND
CULTIVATION
OF
HUMAN
CD34
+
CELLS
.
42
2.3.4.
FLOW
CYTOMETRY
ANALYSIS
.
42
2.3.5.
PREPARATION
OF
VIRUS
STOCKS
.
44
2.3.6.
TITRATION
OF
VIRUS
PARTICLES
(TCID50)
.
45
2.3.7.
INFECTION
OF
CELLS
.
45
2.3.8.
COLONY-FORMING
ASSAYS
.
47
2.3.9.
VIRUS
GROWTH
KINETICS
.
47
2.3.10.
KILLING
KINETICS
AND
DOSE
DEPENDENCY
.
48
2.3.11.
BYSTANDER
ASSAY
.
49
2.4.
ANIMAL
EXPERIMENTS
.49
2.4.1.
SUBCUTANEOUS
HUH7
XENOGRAFT
CELL
IMPLANTATION
.
50
2.4.2.
ORTHOTOPIC
GLIOMA
SPHERE
CELL
IMPLANTATION
.
51
2.4.3.
ADMINISTRATION
OF
VIRUS
PARTICLES
.
52
2.4.4.
TRANSCARDIAL
PERFUSION
.
53
2.4.5.
EX
VIVO
SPHERE
FORMATION
ASSAYS
.
53
2.4.6.
CRYO
EMBEDDING
AND
IMMUNOFLUORESCENCE
STAINING
OF
TUMOR
SECTIONS
.54
2.4.7. PARAFFIN
EMBEDDING
AND
IMMUNOHISTOCHEMISTRY
OF
BRAIN
SECTIONS
.
54
2.4.8.
QUANTIFICATION
OF
INFECTED
AREAS
IN
CRYO
SECTIONS
OF
TUMOR
TISSUE
.
55
2.5.
STATISTICAL
ANALYSIS
.
56
3.
R
ESULTS
.
57
3.1.
CHARACTERIZATION
OF
ONCOLYTIC
VIRUSES
FOR
PROTEIN
COMPOSITION
.
58
3.2.
SELECTIVITY
OF
TARGETED
ONCOLYTIC
VIRUSES
.
58
3.3.
REPLICATION
OF
TARGETED
ONCOLYTIC
VIRUSES
ON
HUH7
HEPATOCELLULAR
CARCINOMA
CELLS
.
60
3.4.
TOXICITY
TESTING
OF
CD133-TARGETED
ONCOLYTIC
VIRUSES
TOWARDS
HUMAN
CD34
+
CELLS
.
62
3.4.1.
ANALYSIS
OF
HUMAN
CD34
+
CELLS
FOR
SUSCEPTIBILITY
TO
INFECTION
.
63
3.4.2.
EVALUATION
OF
IMPAIRMENT
OF
HEMATOPOIETIC
STEM
CELL
SELF-RENEWAL
AFTER
INFECTION
.
65
3.5.
ONCOLYTIC
PROPERTIES
ON
CULTURED
CELLS
.
67
3.5.1.
INFECTION
OF
HEPATOCELLULAR
CARCINOMA
CELLS
.
67
3.5.2.
POTENTIATED
ONCOLYSIS
OF
MV
SCD
-CD133
THROUGH
BYSTANDER-MEDIATED
KILLING
OF
TARGET-RECEPTOR
NEGATIVE
CELLS
.
70
3.6.
ONCOLYTIC
PROPERTIES
ON
PRIMARY
TUMOR
CELLS
.
71
3.6.1.
CELL
SURFACE
EXPRESSION
LEVELS
OF
CD46
AND
CD133
ON
NCH644
CELLS.
73
3.6.2.
TIME
AND
DOSE
RESPONSE
KILLING
OF
PRIMARY
GLIOMA
SPHERE
CELLS
.
74
3.6.3.
ENHANCED
KILLING
OF
PRIMARY
GLIOMA
SPHERE
CELLS
BY
MV
SCD
-CD133
.
76
3.7.
EFFICACY
IN
VIVO
.
77
3.7.1.
ACTIVITY
OF
INTRATUMORALLY
APPLIED
CD133-TARGETED
VIRUSES
IN
A
SUBCUTANEOUS
XENOGRAFT
MODEL
OF
HEPATOCELLULAR
CARCINOMA
.
77
3.7.2.
CHARACTERIZATION
OF
EXPLANTED
TUMORS
INFECTED
WITH
MV-CD133
AND
VSV-CD133
.
79
3.7.3.
ACTIVITY
OF
SYSTEMICALLY
ADMINISTERED
CD133-TARGETED
VIRUSES
AGAINST
A
SUBCUTANEOUS
XENOGRAFT
MODEL
OF
HEPATOCELLULAR
CARCINOMA
.
85
3.7.4.
ACTIVITY
OF
CD133-TARGETED
VIRUSES
IN
AN
ORTHOTOPIC
GLIOMA
MODEL
.
85
3.7.5.
DIRECT
INTRACRANIAL
APPLICATION
OF
ONCOLYTIC
VIRUSES
INTO
NAIVE
MICE
.
91
4.
D
ISCUSSION
.
93
4.1.
CD133
AS
TARGET
RECEPTOR
.
93
4.2.
NEUROTOXICITY
.
98
4.3.
CLINICAL
APPLICATION
OF
RECEPTOR-TARGETED
ONCOLYTIC
VIRUSES
.
102
R
EFERENCES
.
105
L
IST
O
F
P
UBLICATIONS
.
124
D
ANKSAGUNG
.
127
E
HRENWORTLICHE
E
RKLARUNG
.
128 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Schadel, Dina |
| author_GND | (DE-588)1212543882 |
| author_facet | Schadel, Dina |
| author_role | aut |
| author_sort | Schadel, Dina |
| author_variant | d s ds |
| building | Verbundindex |
| bvnumber | BV046896117 |
| ctrlnum | (OCoLC)1159698420 (DE-599)HEB465982492 |
| discipline | Agrar-/Forst-/Ernährungs-/Haushaltswissenschaft / Gartenbau Medizin |
| discipline_str_mv | Agrar-/Forst-/Ernährungs-/Haushaltswissenschaft / Gartenbau Medizin |
| edition | 1. Auflage |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02062nam a2200577 c 4500</leader><controlfield tag="001">BV046896117</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">200911s2020 gw a||| m||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">20,B35</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">20,H09</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1215046308</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783863455347</subfield><subfield code="c">Broschur</subfield><subfield code="9">978-3-86345-534-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1159698420</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HEB465982492</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-188</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">630</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">616.994</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schadel, Dina</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1212543882</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors</subfield><subfield code="c">eingereicht von Dina Schadel, geb. Kleinlützum</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Gießen</subfield><subfield code="b">DVG Service GmbH</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">IX, 128 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">21 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">Justus-Liebig-Universität Gießen</subfield><subfield code="d">2019</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">cell lines</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">viruses</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">antibodies</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">neoplasms</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">growth models</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Onkolytische Viren</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Glioblastoma Multiforme</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HepatozellulÃres Karzinom</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Krebsstammzellen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD133</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Oncolytic Viruses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Glioblastoma Multiforme</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hepatocellular Carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer Stem Cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CD133</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">https://d-nb.info/1215046308/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032305876&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032305876</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV046896117 |
| illustrated | Illustrated |
| index_date | 2024-07-03T15:22:41Z |
| indexdate | 2024-07-10T08:56:50Z |
| institution | BVB |
| isbn | 9783863455347 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032305876 |
| oclc_num | 1159698420 |
| open_access_boolean | |
| owner | DE-188 |
| owner_facet | DE-188 |
| physical | IX, 128 Seiten Illustrationen, Diagramme 21 cm |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | DVG Service GmbH |
| record_format | marc |
| spelling | Schadel, Dina Verfasser (DE-588)1212543882 aut Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors eingereicht von Dina Schadel, geb. Kleinlützum 1. Auflage Gießen DVG Service GmbH 2020 IX, 128 Seiten Illustrationen, Diagramme 21 cm txt rdacontent n rdamedia nc rdacarrier Dissertation Justus-Liebig-Universität Gießen 2019 cell lines cabt viruses cabt antibodies cabt neoplasms cabt growth models cabt Onkolytische Viren Glioblastoma Multiforme HepatozellulÃres Karzinom Krebsstammzellen CD133 Oncolytic Viruses Hepatocellular Carcinoma Cancer Stem Cells (DE-588)4113937-9 Hochschulschrift gnd-content B:DE-101 application/pdf https://d-nb.info/1215046308/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032305876&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Schadel, Dina Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors cell lines cabt viruses cabt antibodies cabt neoplasms cabt growth models cabt |
| subject_GND | (DE-588)4113937-9 |
| title | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors |
| title_auth | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors |
| title_exact_search | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors |
| title_exact_search_txtP | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors |
| title_full | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors eingereicht von Dina Schadel, geb. Kleinlützum |
| title_fullStr | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors eingereicht von Dina Schadel, geb. Kleinlützum |
| title_full_unstemmed | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors eingereicht von Dina Schadel, geb. Kleinlützum |
| title_short | Comparative studies of recombinant oncolytic viruses for the treatment of CD133-positive tumors |
| title_sort | comparative studies of recombinant oncolytic viruses for the treatment of cd133 positive tumors |
| topic | cell lines cabt viruses cabt antibodies cabt neoplasms cabt growth models cabt |
| topic_facet | cell lines viruses antibodies neoplasms growth models Hochschulschrift |
| url | https://d-nb.info/1215046308/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=032305876&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT schadeldina comparativestudiesofrecombinantoncolyticvirusesforthetreatmentofcd133positivetumors |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis